Key result
Treatment with the cationic acrylate polymer Eudragit E100 induced a dose-dependent inhibition of enveloped virus infectivity and reduced HIV and HCV RNA plasma levels to undetectable values.
Why the study?
Does Eudragit E100 reduce virus infectivity in lipid-enveloped viruses and infected human sera?
Does Eudragit E100 reduce virus infectivity in lipid-enveloped viruses and infected human sera?
Eudragit E100 demonstrates potent antiviral activity against lipid-enveloped viruses, including HIV and HCV, reducing viral loads to undetectable levels even in the presence of proteins.
Answers are grounded in this paper and cite their sources.
May support cationic polymers for enveloped virus control; hypothesis-generating from animal data and requires human trials.
The antiviral effects of the cationic acrylate polymer E100 on a panel of lipid-enveloped viruses and the interactions involved are studied. The treatment of several common viruses with E100 induced a dose-dependent inhibition of the infectivity of viruses below the detection limit of the assays employed. Similarly, the treatment of human sera infected with HIV or HCV reduced virus RNA plasma levels to undetectable values. This implies that Eudragit E100 can interact with enveloped viruses, even in the presence of proteins, through a mechanism that is not reversed by titration of the positively charged groups of the polymer, opening the possibility to remove viral particles with the polymer as it is eliminated.
No takes yet. Share an insight, caveat, or question.
Alasino et al. (2007) studied Lipid-enveloped viruses (HIV, HCV). Cationic acrylate polymer Eudragit E100 was evaluated on Virus infectivity and virus RNA plasma levels. Treatment with the cationic acrylate polymer Eudragit E100 induced a dose-dependent inhibition of enveloped virus infectivity and reduced HIV and HCV RNA plasma levels to undetectable values.
Synapse has enriched 10 related papers. Consider them for comparative context: